News Extraction Research
Willow Biosciences begins first CBG production

Vancouver-based biotech company, Willow Biosciences Inc. is getting ready for its 500-litre pilot production run to deliver samples of its first cannabinoid, cannabigerol.

Cannabigerol, or CBG, is one of more than 120 identified cannabinoid compounds found in cannabis. It is the non-acidic form of cannabigerolic acid, the parent molecule from which other cannabinoids are synthesized.

Early research suggests that CBG has a range of bioreactive properties in the body that include anti-microbial and antioxidant functions. It is also said to be one of the most expensive cannabinoids to produce and Willow will be the first to biosynthetically produce material amounts.

“To a very large degree we will look upon this time as a watershed moment for our industry,” said Chris Savile, Willow’s chief operating officer. “We will finally be able to pivot to a variety of cannabinoid choices that best match our customers’ needs. Through our manufacturing methods we can achieve these solutions, and continue to assure our customers of category-altering purity, quality and safety.”

Willow is a Canadian biotechnology company that produces high purity, plant-derived compounds for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications.